GlassScriptPhysician profile
Raymond S Duong
NPI 1154437077
$2,547.45
in general payments reported to CMS, 2019-2025
25 companies · $120 in 2025
The $120 reported for 2025 was less than what a typical Internal Medicine provider received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $685 · 2020: $441 · 2021: $396 · 2022: $298 · 2023: $310 · 2024: $297 · 2025: $120.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $593 · Education: $134.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $593.33 |
| Education | $133.88 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $718.16 | 2019-2025 | Repatha, Otezla, Repatha |
| Pfizer INC. | $364.07 | 2019-2024 | |
| Novo Nordisk INC | $192.45 | 2019-2022 | |
| Esperion Therapeutics, INC. | $144.62 | 2020-2025 | Nexletol |
| Astellas Pharma US INC | $116.35 | 2023 | Veozah |
| Biogen, INC. | $104.85 | 2020-2022 | |
| Boston Scientific Corporation | $101.05 | 2019 | |
| Glaxosmithkline, LLC. | $97.17 | 2019-2023 | Trelegy Ellipta |
| Amarin Pharma, INC. | $93.73 | 2019-2020 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $80.56 | 2019-2021 | |
| Novartis Pharmaceuticals Corporation | $71.06 | 2019-2022 | |
| Currax Pharmaceuticals LLC | $67.84 | 2022-2023 | Nexletol, Contrave, Onzetra Xsail |
| Lilly USA, LLC | $55.95 | 2023-2024 | Mounjaro, Jardiance, Trulicity |
| Exact Sciences Corporation | $49.21 | 2025 | Cologuard Collection Kit |
| Bayer Healthcare Pharmaceuticals INC. | $40.94 | 2022 |
Show all 25 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Sunovion Pharmaceuticals INC. | $37.56 | 2022 | |
| Astrazeneca Pharmaceuticals LP | $34.21 | 2019-2020 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $30.56 | 2019 | |
| Allergan, INC. | $29.82 | 2019 | |
| Acella Pharmaceuticals, LLC | $28.12 | 2019 | |
| Abbvie INC. | $27.72 | 2020-2024 | |
| Janssen Pharmaceuticals, INC | $17.80 | 2019 | |
| Radius Health, INC. | $15.40 | 2021 | |
| Idorsia Pharmaceuticals US INC | $15.00 | 2024 | Quviviq |
| Scilex Pharmaceuticals INC. | $13.25 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Raymond Duong listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.